LOGIN  |  REGISTER
Amneal Pharmaceuticals
Terns Pharmaceuticals

FDA Roundup: August 29, 2023

Silver Spring, MD / August 29, 2023 / Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: 

  • On Monday, the FDA informed consumers in Treating and Dealing with ADHD about FDA-approved treatments to help reduce the symptoms of attention-deficit/hyperactivity disorder, also known as ADHD, and improve functioning in children as young as age 6 years old.

  • On Friday, the American Dental Association Science and Research Institute, the University of Pittsburgh School of Dental Medicine, and the Center for Integrative Global Oral Health at the University of Pennsylvania School of Dental Medicine issued a new clinical practice guideline detailing dental pain management strategies for childrenExternal Link Disclaimer. The development of this guideline was funded by an FDA-provided grant. An FDA-commissioned report by the National Academies of Science, Engineering, and Medicine recommended that the guideline be developed.

  • On Friday, the Interagency Food Safety Analytics Collaboration (IFSAC) — a collaboration between the Centers for Disease Control and Prevention (CDC), the U.S. Food and Drug Administration (FDA), and the USDA Food Safety and Inspection Service (FSIS) — published its upcoming priorities for calendar years 2024 - 2028.

###

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

C4 Therapeutics

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB